Nov 2 (Reuters) - Tiziana Life Sciences said on Monday its experimental therapy for a progressive form of multiple sclerosis with no approved treatments reduced brain inflammation and showed a ...
Health Canada has approved Ocrevus for children 10 and older with relapsing-remitting MS, expanding treatment options for ...
A Phase 2 trial found that a lower dose of nasal foralumab significantly reduced brain inflammation markers in people with nonactive SPMS.
Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on October 23, 2026, Health Canada approved Ocrevus IV, ...
A multiple sclerosis treatment from Novartis cut by a third the rates of relapses that people with the condition have ...
The Global Multiple Sclerosis Treatment Market Report 2025 provides a comprehensive analysis of market trends, multiple sclerosis prevalence, patient population, disease burden, treatment adoption, ...
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteersAchieved full central ...
Treatment with the anti-CD20 medication rituximab was linked to a nearly 10-fold increased risk for inflammatory bowel disease (IBD) in patients with relapsing-remitting multiple sclerosis (MS).
Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...
Agreement expands Neurophet's reach into U.S. health systems and builds on RapidAI's leadership in enterprise clinical AI and neurosciences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results